- TiGenix NV (NASDAQ:TIG) announces that the Company plans to focus its resources and capabilities on its expanded adipose-derived stem cells (eASC) platform technology and its product candidates Cx601 and Cx611.
- This decision follows the recent positive CHMP opinion for Cx601 to treat complex perianal fistulas in Crohn's disease.
- The Company has undertaken a scoping exercise and have identified three new attractive indications where it plans to develop Cx601 to expand its addressable market.
- TiGenix is also advancing its Phase I/II clinical SEPCELL trial to evaluate Cx611 for the treatment of severe sepsis secondary to community-acquired pneumonia in patients who require mechanical ventilation and/or vasopressors.
- TiGenix will not be investing in further R&D of its allogeneic cardiac stem cell technology and will review alternatives for further investment in this technology.
- Shares are up 1% premarket on modest volume
- Now read: Your Daily Pharma Scoop: Aclaris Gets Approval, Egalet Surges, Alnylam Gains As FDA Lifts Clinical Hold
Original article